Abstract
Background In rheumatoid arthritis (RA) patients, it is important to evaluate renal function, because it may deteriorate due to RA itself or drug use requiring drug dose adjustment. Recently, Cystatin C (CysC) has been used as a more accurate marker of renal function than Creatinine (Cr), because it is not affected by muscle mass.1) Renal function of some RA patients is overestimated by Cr, and shows a discrepancy in the estimated glomerular filtration between Cr and CysC. However, what factors contribute to this discrepancy and in what RA patients CysC should be evaluated remain to be elucidated. Objectives To clarify the factors contributing to the discrepancy between eGFR measured using Cr (eGFR-Cr) and CysC(eGFR-CysC). Methods We enrolled 236 RA patients (188 females, 48 males; mean age 65.3±14.0 years; disease duration 12.0 ± 11.0 years). We measured BUN, Cr, CysC, IgG, IgA, IgM, C3,C4, CH50, RF and aCCP in patient serum, urinary proteins, urinary blood, and urinary casts and evaluated CDAI, SDAI, disease activity score (DAS) 28-CRP and DAS28-ESR. Steinbrocker functional classification and radiological grading were evaluated. History of diabetes mellitus, hypertension and hyperlipidemia was determined from the medical records. Estimated glomerular filtration rate (eGFR) was calculated by the new Japanese coefficient-modified Modification of Diet in Renal disease (MDRD) study equation. Results The eGFR-Cr and eGFR-CysC of RA patients were 72.5±20.2 (12.0∼142.0) and 72.3±24.9 (6.3∼167.8), with no significant difference between the two. The correlation between them was significant (r=0.715, p Conclusion Renal functions of RA patients with high disease activity, diabetes mellitus, advanced stage, anemia or lower CK could be overestimated when judged using eGFR-Cr alone. Assessment of renal function in such RA patients requires particular attention. Reference [1] Nozawa Y, Sato H, Wakamatsu A, et al. Utility of estimated glomerular filtration rate using cystatin C and its interpretation in patients with rheumatoid arthritis under glucocorticoid therapy. Clin Chim Acta2018; 487, 299-305. Disclosure of Interests None declared
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.